Last reviewed · How we verify
NCT06773715
Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain
NA trial testing KindVR Aqua Program in Sickle Cell Disease in 36 participants. Currently enrolling.
19 December 2025
Quick facts
| Lead sponsor | Louisiana State University Health Sciences Center in New Orleans |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 36 |
| Start date | 12 September 2024 |
| Primary completion | 19 December 2025 |
| Estimated completion | 19 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- KindVR Aqua Program
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
- Vaso-occlusive Pain Episodes — all drugs for Vaso-occlusive Pain Episodes →
Sponsor
Louisiana State University Health Sciences Center in New Orleans
Who can join
Adults 8 to 21, any sex, with Sickle Cell Disease or Vaso-occlusive Pain Episodes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are: Does virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis? Does virtual reality decrease the daily use of opiates? Researchers will compare standard therapy to the use of standard therapy plus a daily virtual reality experience to see if virtual reality works to treat sickle cell pain. All patients will: \- Be asked to fill out a pain assessment survey three times daily for up to 3 days If randomized to intervention arm, patients will: * Participate in an immersive virtual reality experience once daily for up to 3 days * Fill out a survey twice daily to monitor for side effects from virtual reality experience * Fill out a satisfaction survey once during the study period
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06773715
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other Louisiana State University Health Sciences Center in New Orleans trials
Trials by the same sponsor.
- NCT07462767 — Precision Microbiota Interventions for Senoreduction Trial · Phase 1, PHASE2 · not yet recruiting
- NCT07488156 — Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder · NA · not yet recruiting
- NCT07280260 — Clinical Performance of Nobel N1 System · Phase 4 · recruiting
- NCT06874244 — Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery · EARLY_PHASE1 · completed
- NCT06342973 — Horizontal Ridge Augmentation With Demineralized Bone Allograft Layered With Xenograft - a Prospective Clinical Study · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06773715 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Louisiana State University Health Sciences Center in New Orleans
- Last refreshed: 14 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06773715.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing